X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action, led to reduced colon and skin inflammation.
Lead Product(s): GIGA-564
Therapeutic Area: Oncology Product Name: GIGA-564
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Details:
The agreement aims to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564, a fully human monoclonal antibody, distinguishes itself from currently available anti-CTLA-4 drugs.
Lead Product(s): GIGA-564
Therapeutic Area: Oncology Product Name: GIGA-564
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 28, 2023
Details:
Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic's technology platform to the development and manufacturing of its mono- and polyclonal antibody drug candidates.
Lead Product(s): Recombinant Polyclonal Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Recipient: ProteoNic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 01, 2022
Details:
As part of this award, GigaGen will demonstrate its platform’s capabilities by producing recombinant human hyperimmune products that target DOD-priority pathogens, including a recombinant polyclonal antibody drug designed to neutralize botulinum neurotoxins A and B.
Lead Product(s): Recombinant Human Polyclonal Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 15, 2022
Details:
GIGA-2050 is comprised of more than 12,000 antibodies demonstrating strong neutralizing activity against natural SARS CoV-2 variants in laboratory studies, including the delta variant and other variants that have emerged globally since the beginning of the pandemic.
Lead Product(s): GIGA-2050
Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo through a unique mechanism of action, led to reduced colon and skin inflammation.
Lead Product(s): GIGA-564
Therapeutic Area: Oncology Product Name: GIGA-564
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Under the agreement, GigaGen gains non-exclusive, worldwide commercial rights for application of ProteoNic’s technology platform for the development and manufacturing of GigaGen’s recombinant antibody drugs including GIGA-2050.
Lead Product(s): GIGA-2050
Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ProteoNic
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 30, 2021
Details:
GIGA-2050 comprises more than 12,000 antibodies, encompassing a diverse set of anticoronavirus antibodies captured from the convalescent blood of 16 exceptional responders to COVID-19.
Lead Product(s): GIGA-2050
Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Grifols International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 09, 2021
Details:
Company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), Waisman Biomanufacturing and Goodwin Biotechnology, Inc.
Lead Product(s): GIGA-2050
Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2020
Details:
GigaGen's new data highlights a new class of polyclonal antibody drugs, termed recombinant hyperimmunes, which comprise thousands to tens of thousands of antibodies. These are derived from donor B cells, and are produced recombinantly at large scale in mammalian cells.
Lead Product(s): GIGA-2050
Therapeutic Area: Infections and Infectious Diseases Product Name: GIGA-2050
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
